Miracor Medical Systems has announced the first treatments of patients with the PiCSO impulse system in the United Arab Emirates (UAE), marking the launch of this novel therapy in Asia in cooperation with Medical Technology.
The first cases using the PiCSO impulse system have been performed by Arif Al Nooryani, chief executive officer and head of Cardiac Center and his team at Al Qassimi Hospital, the largest public hospital in Sharjah emirate and largest hospital under the umbrella of the Federal Ministry of Health in the UAE.
“We applied PiCSO therapy during complex percutaneous coronary intervention (PCI) procedures, treating non-ST-elevation myocardial infarction patients,” said Arif Al Nooryani. “Directly following diagnostic angiography, we initiated PiCSO therapy for the duration of the complex stenting procedures to improve myocardial perfusion. I was impressed to see the immediate effect of PiCSO, as my patients did not experience chest pain, nor did we see electrocardiogram changes or signs of no-reflow phenomena, which can normally be expected during such procedures,” he continued. “This demonstrates the positive effects of PiCSO on myocardial perfusion. I now look forward to making this therapy available for our acute myocardial infarction patients at Al Qassimi Hospital.”
The procedures in the UAE were performed with the support of Access Medical, a UAE-based medical devices distributor and sister company of Medical Technology, which is now co-operating with Miracor to launch the PiCSO system in Saudi Arabia, Kuwait and Oman.
“The launch of PiCSO in Asia marks an important milestone in the ongoing commercialisation of PiCSO worldwide,” says Lars Schiemanck, managing director of Miracor. “Integrating PiCSO therapy into regular PCI procedures without interrupting the workflow of the cath lab was made possible by the introduction of Miracor’s second generation device in 2014. This has been demonstrated in clinical use in Europe and greatly expands the potential use of PiCSO therapy. Our goal is to make this innovative therapy available to acute myocardial infarction patients worldwide.”
